Vinflunine for the treatment of breast cancer
C Gourmelon, H Bourien, P Augereau… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Breast cancer is the most frequently diagnosed cancer and the highest cause of
cancer mortality in females worldwide. The development of drugs improving overall survival …
cancer mortality in females worldwide. The development of drugs improving overall survival …
A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer
K Zaman, X Durando, JF Baurain, Y Humblet… - Breast cancer research …, 2011 - Springer
Vinfunine (VFL) is a novel bifluorinated tubulin-targeted agent of the vinca alkaloids class
active in advanced stage breast cancer. We conducted a phase I study combining VFL with …
active in advanced stage breast cancer. We conducted a phase I study combining VFL with …
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer
S Chan, M Campone, A Santoro, PF Conte… - Cancer chemotherapy …, 2014 - Springer
Background Vinflunine (VFL) is a bifluorinated tubulin-targeted agent of the vinca alkaloids
class active in advanced stage breast cancer. We conducted a phase I study combining VFL …
class active in advanced stage breast cancer. We conducted a phase I study combining VFL …
[HTML][HTML] Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer
M Blasinska-Morawiec, N Tubiana-Mathieu… - The Breast, 2013 - Elsevier
PURPOSE: This open label phase II study evaluated the safety and efficacy of vinflunine in
patients with breast cancer previously treated with a vinorelbine-based regimen and who …
patients with breast cancer previously treated with a vinorelbine-based regimen and who …
[HTML][HTML] Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer
J Cortes, J Perez-Garcia, C Levy, PG Pardo… - Annals of …, 2018 - Elsevier
Background There is no standard treatment after progression on second-line chemotherapy
for metastatic breast cancer (MBC). We compared vinflunine with physician's choice of …
for metastatic breast cancer (MBC). We compared vinflunine with physician's choice of …
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first …
M Campone, H Cortes-Funes, D Vorobiof… - British journal of …, 2006 - nature.com
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
targeted agent vinflunine (VFL)(320 mg m− 2 q 21 days) as second-line chemotherapy in …
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M Campone, N Isambert, E Bourbouloux… - Cancer chemotherapy …, 2012 - Springer
Purpose A phase I study was performed to determine the maximal tolerated dose (MTD),
recommended dose (RD), safety and efficacy of vinflunine when combined with …
recommended dose (RD), safety and efficacy of vinflunine when combined with …
New vinca alkaloids in clinical development
P Fumoleau, S Guiu - Current Breast Cancer Reports, 2013 - Springer
The most successful tubulin-targeting agents in the treatment of breast cancer are the
taxanes and the Vinca alkaloids. Vinorelbine, a vinca alkaloid derivative, has remarkable …
taxanes and the Vinca alkaloids. Vinorelbine, a vinca alkaloid derivative, has remarkable …
Phase II study of iv vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure
P Fumoleau, M Campone, D Vorobiof… - Journal of Clinical …, 2004 - ascopubs.org
542 Background: The aim of this study was to assess efficacy and safety of vinflunine
(Javlor), a novel semi-synthetic vinca alkaloid, in patients with metastatic breast cancer who …
(Javlor), a novel semi-synthetic vinca alkaloid, in patients with metastatic breast cancer who …
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy
P Fumoleau, H Cortés-Funes, AB Taleb… - American journal of …, 2009 - journals.lww.com
Objective: A multicenter, open-label, phase 2 study evaluated the efficacy and safety of
intravenous vinflunine as third-line treatment in patients with progressing metastatic breast …
intravenous vinflunine as third-line treatment in patients with progressing metastatic breast …